Previous 10 | Next 10 |
2023-05-15 15:05:44 ET Summary Today, we take our first look at Maravai LifeSciences Holdings, Inc which was the subject of new takeover rumors last week. Both business segments of this nucleic acid production and biologics safety testing have seen sales fall drastically thanks to...
2023-05-10 22:19:06 ET Dyadic International, Inc. (DYAI) Q1 2023 Earnings Conference Call May 10, 2023 05:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Of...
2023-05-10 16:21:22 ET Dyadic International press release ( NASDAQ: DYAI ): Q1 GAAP EPS of -$0.03. Revenue of $0.98M (+50.8% Y/Y). For further details see: Dyadic International GAAP EPS of -$0.03, revenue of $0.98M
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human health Expanded licensing agreement with Rubic One Health (“Rubic”) to develop, manufacture and commercialize affordable vaccines and biologics for human and an...
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and ...
JUPITER, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to add...
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to a...
2023-04-18 09:50:51 ET Dyadic International ( NASDAQ: DYAI ) stock rose ~6% on Tuesday after the company said it received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for an application covering claims for developing and making seasonal and pandemic ...
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein produc...
JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein biopro...
News, Short Squeeze, Breakout and More Instantly...
Dyadic International Inc. Company Name:
DYAI Stock Symbol:
OTCMKTS Market:
Dyadic International Inc. Website:
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for ...
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well a...
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against C...